about
Chemoprevention for colon cancer: new opportunities, fact or fiction?Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma.Treatment strategies in gastric cancer.Cost-effectiveness of colorectal cancer screening in high-risk Spanish patients: use of a validated model to inform public policyGastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidenceIncreasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trialFluorescence in situ hybridisation analysis of chromosomal aberrations in gastric tissue: the potential involvement of Helicobacter pyloriZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine.BML-275, an AMPK inhibitor, induces DNA damage, G2/M arrest and apoptosis in human pancreatic cancer cellsHistopathologic Prolife of Primary Gastrointestinal Malignancies in Uyo City (Niger-Delta Region of Nigeria).Colorectal Carcinomas in Uyo City, Southern Geopolitical Zone of Nigeria: A Review of Clinicopathological Characteristics and Literature.Human development index is associated with mortality-to-incidence ratios of gastrointestinal cancers.Ethical issues in the management of elderly patients in gastroenterology and digestive endoscopy.Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.Proposed score for the self-assessment of an endoscopy department performance in colonoscopy screening.Monitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer.Prognostic value of HIF-1α expression in patients with gastric cancer.Piecemeal mucosectomy, submucosal dissection or transanal microsurgery for large colorectal neoplasm.p8 expression controls pancreatic cancer cell migration, invasion, adhesion, and tumorigenesis.A Risk Prediction Model for Sporadic CRC Based on Routine Lab Results.bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells.Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer.Helicobacter pylori infection and gastroesophageal cancer: unveiling a Hamletic dilemma.Card15 mutations and gastric cancer in a Portuguese population.Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer.Upper GI endoscopy in elderly patients: predictive factors of relevant endoscopic findings.Prospective comparison of MR with diffusion-weighted imaging, endoscopic ultrasound, MDCT and positron emission tomography-CT in the pre-operative staging of oesophageal cancer: results from a pilot study.Possible Predictive Markers of Response to Therapy in Esophageal Squamous Cell Cancer.Could the colonic capsule PillCam Colon be clinically useful for selecting patients who deserve a complete colonoscopy?: results of clinical comparison with colonoscopy in the perspective of colorectal cancer screening.Endoscopic traversability in patients with locally advanced esophageal squamous cell carcinoma: Is it a significant prognostic factor?The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3).THE DISTRIBUTION, HISTOLOGIC PROFILE AND CLINICAL PRESENTATION OF GASTROINTESTINAL MALIGNANCIES IN LAGOS, NIGERIA.Impact of Sarcopenia in Patients with Unresectable Locally Advanced Esophageal Cancer Receiving Chemoradiotherapy.
P2860
Q28219247-22648C6E-DDD2-455B-BEFE-84BEDDEE52F9Q33866015-27C28E4E-97E2-4543-BC0A-77E5ACCE33E2Q34082714-3D7E5728-5D2F-49D5-B057-B3004AD27CAFQ35173359-FF26402D-6F79-4F12-AFC6-26B4AFC1BD8DQ35768888-21E9CFF9-178B-4B42-BEF8-6D53C12E7DB1Q36610386-B2719CD8-A649-4E34-9E59-27E20266CB1DQ36611661-23BE8341-0541-4BEB-BB38-E43CC361CA06Q36616789-8F072AE9-E7D1-49B4-9ED8-749E77D28296Q36625098-42C046FA-71B0-4926-B0FC-67159B7F3B55Q36642909-9F8E62E7-4151-4407-9992-C7D3F8BF05EEQ36787140-60783C41-DB31-4A66-B3B2-5FDC42A8C1CFQ37072598-86876D52-E0E0-4F39-A62C-33D3228796C6Q37118820-7AEDDF7F-826C-407E-9C5D-8D4EB1087611Q37345992-F3886496-B291-4E6F-910C-1CAD19BF33CBQ37400545-47F77D01-921A-46E6-976C-9A04192AED95Q37638874-33DD7EF3-BCEC-4CD4-B5C5-265AA030CABCQ37681293-62B1290A-7614-490F-8BC1-6CC7261DD078Q38140678-F19DACE6-EC5F-45A3-BCA7-CCF7B8D1AC7EQ38289719-34B5F2F9-7D38-4ABF-A32C-E92AE7828421Q39587471-FA4D0723-10E9-4053-9226-A8F02C273803Q39984658-7BD199DC-FCE7-4218-97A1-F4CCFE531ADCQ40155540-B4A87CA2-69CD-4069-B237-5D40AAB6DD2DQ40385543-D0DAD3E7-B418-4844-BF04-E10644AB623BQ41694363-27E72705-AD41-4CBE-9598-E482410F7CE0Q44402017-5DBE34D1-4E57-44D0-A85D-0B8D14DACF88Q44892640-D6301ED6-5F01-453C-BC7D-5A91238F1744Q46353178-3DDD93C6-BB3D-4609-B00F-BC4680787E87Q46599872-8A248C5E-7DCE-4B4B-891F-2485C131033FQ47441119-9E852FA1-D550-4756-8FC7-C26ACB52C98FQ48399026-8A595350-C520-4D29-9210-66575A7915E1Q49164810-7BC4FAEE-4DEE-4EDA-8ED8-B32CA67FACDBQ53107664-2625F456-54EB-4F25-802A-224AD86FC79EQ55310665-48E813A7-4F56-4B5A-9C28-11079D555682Q55428382-13BAAA14-B58B-4CCA-A8EC-5E59C8B53556
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Gastrointestinal cancers in Europe.
@ast
Gastrointestinal cancers in Europe.
@en
type
label
Gastrointestinal cancers in Europe.
@ast
Gastrointestinal cancers in Europe.
@en
prefLabel
Gastrointestinal cancers in Europe.
@ast
Gastrointestinal cancers in Europe.
@en
P2860
P1476
Gastrointestinal cancers in Europe.
@en
P2093
Keighley MR
P2860
P356
10.1046/J.0953-0673.2003.01722.X
P407
P478
18 Suppl 3
P577
2003-11-01T00:00:00Z